NCT02216266.

Trial name or title	Monocentre, double‐blind, randomised, placebo‐controlled study to evaluate physostigmine for the treatment of delirium in perioperative intensive care medicine
Methods	Single‐site, triple‐blind, randomized placebo‐controlled study taking place in Germany. Target enrolment: 120 participants
Participants	Adult (18 to < 85 years) ICU patients post elective or emergency heart surgery (with or without extracorporeal circulation) diagnosed with delirium via the CAM‐ICU
Interventions	Participants randomized to receive physostigmine or placebo, administered intravenously at a dose of 24 mg + 25 minutes at 0.04 mg/kg
Outcomes	Primary Change in delirium symptoms measured by RASS Secondary Duration of mechanical ventilation Change in spontaneous EEG and auditory evoked potential Heart rate variability Muscular force (via force gauge) Adverse events.
Starting date	April 2014
Contact information	Bertram Scheller (bertram.scheller@kgu.de)
Notes	Study status unknown, but last updated as recruiting on 10 March 2017 Study sponsor: PD Dr Bertram Scheller Study registered: at clinicaltrials.gov under NCT02216266